Photobiomodulation Plus Neurofeedback Studied in PANS/PANDAS

A retrospective case series published in Frontiers examines combined transcranial photobiomodulation (tPBM) and neurofeedback in children and adolescents with PANS/PANDAS — the inflammatory neuropsychiatric syndromes marked by abrupt-onset obsessive-compulsive symptoms, tics, and cognitive and behavioral regression, frequently following streptococcal or other infection.

The study is a retrospective case series, not a controlled trial. That framing matters for how readers of an EEG-focused publication should weigh it. Case series generate hypotheses; they do not establish efficacy. The authors report outcomes from a combined intervention protocol, and the dataset reflects clinical practice rather than a prospective, blinded design.

PANS/PANDAS sits at an uncomfortable intersection for clinical neurophysiology. The diagnosis is clinical, based on symptom course and temporal association with infection, and it lacks a validated electrophysiological biomarker. QEEG findings reported in this population — including frontal and central dysregulation patterns — remain descriptive. Any claim that neurofeedback "normalizes" EEG in these children must therefore rest on the specific recording and training parameters each study actually used.

In this report, neurofeedback formed one arm of the intervention, paired with transcranial photobiomodulation — low-level light therapy applied transcranially, intended to modulate cortical excitability, cerebral blood flow, and mitochondrial function through near-infrared or red-light exposure. tPBM remains investigational for psychiatric and neuroinflammatory indications. No tPBM device holds FDA clearance for PANS/PANDAS, and clinicians should read the results as exploratory data from an uncontrolled cohort.

For neurofeedback specifically, the relevant methodological questions are the same ones reviewers raise in every series of this kind: what was recorded — the source does not specify montage or referential scheme; how were training targets derived, and whether they rested on normative databases or symptom-based protocols; how many sessions; and who rated outcomes, ideally blinded raters using standardized instruments rather than parent report alone. Retrospective designs rarely answer all of these cleanly, and the present report should be evaluated against that standard.

What the combined approach reflects is a broader shift in the PANS/PANDAS treatment literature: from purely immunomodulatory and antimicrobial strategies toward interventions aimed at the neurophysiological substrate — cortical dysregulation, autonomic instability, and neuroinflammation — that families and clinicians observe in these children. Pairing neuromodulation (tPBM) with operant self-regulation training (neurofeedback) is mechanistically coherent, but coherence is not evidence.

For reading-room and lab practice, the study's practical significance is limited today. No standard of care changes on the basis of a retrospective series. EEG laboratories asked to support neurofeedback protocols in this population should document baseline scalp EEG or QEEG with full technical detail — montage, reference, impedance thresholds, session counts — so that future syntheses can compare like with like. Laboratories already reporting QEEG for clinical decision-making should distinguish descriptive dysregulation findings from validated diagnostic markers, a line that remains sharp in PANS/PANDAS.

The regulatory picture is equally clear-cut. Neurofeedback devices are used in clinical practice under existing frameworks, but protocols targeting PANS/PANDAS specifically are not the subject of cleared indications. tPBM for neuropsychiatric indications is investigational in humans; no pediatric neuroinflammatory claim has cleared review. Anything beyond that characterization would outrun the evidence.

The series also underscores a measurement gap this publication has flagged before: pediatric neuropsychiatric inflammation lacks an agreed electrophysiological endpoint. If tPBM-plus-neurofeedback protocols are to be tested prospectively, investigators will need pre-registered EEG outcome measures — spectral rest-state metrics, event-related potentials, or quantified seizure-risk screening — rather than post hoc waveform impressions.

Prospective controlled trials with standardized EEG acquisition, blinded outcome assessment, and defined tPBM dosimetry will be required before combined neuromodulation can move from case-series plausibility to clinical consideration in PANS/PANDAS.